Safety of niraparib tablets for advanced or relapsed ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial checks the safety of niraparib, a targeted therapy that may help keep ovarian cancer from coming back after chemotherapy. It is for women whose cancer has responded to platinum-based chemotherapy, either as first treatment or after a relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced or relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer has responded (completely or partially) to platinum-based chemotherapy, and you are now considering maintenance treatment.
- Your blood counts and blood pressure are within safe levels for this treatment.
- You have not had a PARP inhibitor treatment before (like olaparib or rucaparib).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study and for 180 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This trial tests a new maintenance therapy called niraparib for Black women who have finished initial treatment for advanced ovarian cancer and are in remission or partial response. It aims to see if the drug is safe and how your body processes it.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.